

# Global Small Interfering RNA (siRNA)-based Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G4542D5CB0FCEN.html>

Date: December 2023

Pages: 86

Price: US\$ 3,480.00 (Single User License)

ID: G4542D5CB0FCEN

## Abstracts

According to our (Global Info Research) latest study, the global Small Interfering RNA (siRNA)-based Therapeutics market size was valued at USD 1035.6 million in 2022 and is forecast to a readjusted size of USD 5308.7 million by 2029 with a CAGR of 26.3% during review period.

Small Interfering RNA (siRNA) drugs are a class of nucleic acid-based therapeutics that utilize short RNA molecules to silence or regulate the expression of specific genes. These drugs have the ability to interfere with the translation of messenger RNA (mRNA) into proteins, effectively 'silencing' the gene associated with that mRNA. SiRNA-based therapies have the potential to treat a variety of diseases, particularly those with a genetic or RNA-based component.

The Small Interfering RNA (siRNA) Drugs Market is driven by the transformative potential of siRNA-based therapies in silencing disease-associated genes, making them a promising approach for treating a wide range of diseases, including genetic disorders, viral infections, and various cancers. siRNA drugs work by selectively degrading or inhibiting the expression of specific genes, offering a highly targeted and personalized treatment option. As the understanding of genomics and RNA interference mechanisms advances, and the need for precision medicine grows, the demand for siRNA drugs continues to rise. Innovations in siRNA design, delivery systems, and gene-editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to overcome delivery barriers, ensure the stability and safety of siRNA therapeutics, and navigate regulatory complexities. Addressing off-target effects, optimizing pharmacokinetics, and managing the high cost of siRNA drug development are ongoing challenges. Additionally, the market faces competition from

traditional therapeutic approaches and the need for continuous research and development to unlock the full therapeutic potential of siRNA drugs. Striking a balance between providing safe, effective, and accessible siRNA therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Small Interfering RNA (siRNA) Drugs Market.

The Global Info Research report includes an overview of the development of the Small Interfering RNA (siRNA)-based Therapeutics industry chain, the market status of AHP (GIVLAARI, Onpattro), hATTR (GIVLAARI, Onpattro), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Small Interfering RNA (siRNA)-based Therapeutics.

Regionally, the report analyzes the Small Interfering RNA (siRNA)-based Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Small Interfering RNA (siRNA)-based Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.

#### Key Features:

The report presents comprehensive understanding of the Small Interfering RNA (siRNA)-based Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Small Interfering RNA (siRNA)-based Therapeutics industry.

The report involves analyzing the market at a macro level:

**Market Sizing and Segmentation:** Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., GIVLAARI, Onpattro).

**Industry Analysis:** Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Small Interfering RNA (siRNA)-based Therapeutics market.

**Regional Analysis:** The report involves examining the Small Interfering RNA

(siRNA)-based Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

**Market Projections:** Report covers the gathered data and analysis to make future projections and forecasts for the Small Interfering RNA (siRNA)-based Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Small Interfering RNA (siRNA)-based Therapeutics:

**Company Analysis:** Report covers individual Small Interfering RNA (siRNA)-based Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

**Consumer Analysis:** Report covers data on consumer behaviour, preferences, and attitudes towards Small Interfering RNA (siRNA)-based Therapeutics. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (AHP, hATTR).

**Technology Analysis:** Report covers specific technologies relevant to Small Interfering RNA (siRNA)-based Therapeutics. It assesses the current state, advancements, and potential future developments in Small Interfering RNA (siRNA)-based Therapeutics areas.

**Competitive Landscape:** By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Small Interfering RNA (siRNA)-based Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

**Market Validation:** The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

**Market Segmentation**

Small Interfering RNA (siRNA)-based Therapeutics market is split by Type and by

Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

#### Market segment by Type

GIVLAARI

Onpattro

OXLUMO

AMVUTTRA

Leqvio

#### Market segment by Application

AHP

hATTR

Other

#### Market segment by players, this report covers

Anylam

Novartis

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Small Interfering RNA (siRNA)-based Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Small Interfering RNA (siRNA)-based Therapeutics, with revenue, gross margin and global market share of Small Interfering RNA (siRNA)-based Therapeutics from 2018 to 2023.

Chapter 3, the Small Interfering RNA (siRNA)-based Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Small Interfering RNA (siRNA)-based Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Small Interfering RNA (siRNA)-based Therapeutics.

Chapter 13, to describe Small Interfering RNA (siRNA)-based Therapeutics research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope of Small Interfering RNA (siRNA)-based Therapeutics

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Small Interfering RNA (siRNA)-based Therapeutics by Type

1.3.1 Overview: Global Small Interfering RNA (siRNA)-based Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029

1.3.2 Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Type in 2022

1.3.3 GIVLAARI

1.3.4 Onpattro

1.3.5 OXLUMO

1.3.6 AMVUTTRA

1.3.7 Leqvio

1.4 Global Small Interfering RNA (siRNA)-based Therapeutics Market by Application

1.4.1 Overview: Global Small Interfering RNA (siRNA)-based Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029

1.4.2 AHP

1.4.3 hATTR

1.4.4 Other

1.5 Global Small Interfering RNA (siRNA)-based Therapeutics Market Size & Forecast

1.6 Global Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast by Region

1.6.1 Global Small Interfering RNA (siRNA)-based Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

1.6.2 Global Small Interfering RNA (siRNA)-based Therapeutics Market Size by Region, (2018-2029)

1.6.3 North America Small Interfering RNA (siRNA)-based Therapeutics Market Size and Prospect (2018-2029)

1.6.4 Europe Small Interfering RNA (siRNA)-based Therapeutics Market Size and Prospect (2018-2029)

1.6.5 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Market Size and Prospect (2018-2029)

1.6.6 South America Small Interfering RNA (siRNA)-based Therapeutics Market Size and Prospect (2018-2029)

1.6.7 Middle East and Africa Small Interfering RNA (siRNA)-based Therapeutics Market Size and Prospect (2018-2029)

## 2 COMPANY PROFILES

### 2.1 Alnylam

2.1.1 Alnylam Details

2.1.2 Alnylam Major Business

2.1.3 Alnylam Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

2.1.4 Alnylam Small Interfering RNA (siRNA)-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 Alnylam Recent Developments and Future Plans

### 2.2 Novartis

2.2.1 Novartis Details

2.2.2 Novartis Major Business

2.2.3 Novartis Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

2.2.4 Novartis Small Interfering RNA (siRNA)-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 Novartis Recent Developments and Future Plans

### 2.3 Sylentis

2.3.1 Sylentis Details

2.3.2 Sylentis Major Business

2.3.3 Sylentis Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

2.3.4 Sylentis Small Interfering RNA (siRNA)-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Sylentis Recent Developments and Future Plans

### 2.4 Arrowhead

2.4.1 Arrowhead Details

2.4.2 Arrowhead Major Business

2.4.3 Arrowhead Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

2.4.4 Arrowhead Small Interfering RNA (siRNA)-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Arrowhead Recent Developments and Future Plans

### 2.5 Silence Therapeutics

2.5.1 Silence Therapeutics Details

2.5.2 Silence Therapeutics Major Business

2.5.3 Silence Therapeutics Small Interfering RNA (siRNA)-based Therapeutics Product



and Solutions

2.5.4 Silence Therapeutics Small Interfering RNA (siRNA)-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.5.5 Silence Therapeutics Recent Developments and Future Plans

2.6 Dicerna

2.6.1 Dicerna Details

2.6.2 Dicerna Major Business

2.6.3 Dicerna Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

2.6.4 Dicerna Small Interfering RNA (siRNA)-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.6.5 Dicerna Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

3.1 Global Small Interfering RNA (siRNA)-based Therapeutics Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Small Interfering RNA (siRNA)-based Therapeutics by Company Revenue

3.2.2 Top 3 Small Interfering RNA (siRNA)-based Therapeutics Players Market Share in 2022

3.2.3 Top 6 Small Interfering RNA (siRNA)-based Therapeutics Players Market Share in 2022

3.3 Small Interfering RNA (siRNA)-based Therapeutics Market: Overall Company Footprint Analysis

3.3.1 Small Interfering RNA (siRNA)-based Therapeutics Market: Region Footprint

3.3.2 Small Interfering RNA (siRNA)-based Therapeutics Market: Company Product Type Footprint

3.3.3 Small Interfering RNA (siRNA)-based Therapeutics Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

### **4 MARKET SIZE SEGMENT BY TYPE**

4.1 Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value and Market Share by Type (2018-2023)

4.2 Global Small Interfering RNA (siRNA)-based Therapeutics Market Forecast by Type

(2024-2029)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

5.1 Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Application (2018-2023)

5.2 Global Small Interfering RNA (siRNA)-based Therapeutics Market Forecast by Application (2024-2029)

## **6 NORTH AMERICA**

6.1 North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2029)

6.2 North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2029)

6.3 North America Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country

6.3.1 North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2018-2029)

6.3.2 United States Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

6.3.3 Canada Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

6.3.4 Mexico Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

## **7 EUROPE**

7.1 Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2029)

7.2 Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2029)

7.3 Europe Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country

7.3.1 Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2018-2029)

7.3.2 Germany Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

7.3.3 France Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

7.3.5 Russia Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

7.3.6 Italy Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2029)

8.3 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Market Size by Region

8.3.1 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Region (2018-2029)

8.3.2 China Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

8.3.3 Japan Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

8.3.4 South Korea Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

8.3.5 India Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

8.3.7 Australia Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

## **9 SOUTH AMERICA**

9.1 South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2029)

9.2 South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2029)

9.3 South America Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country

9.3.1 South America Small Interfering RNA (siRNA)-based Therapeutics Consumption

Value by Country (2018-2029)

9.3.2 Brazil Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

9.3.3 Argentina Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country

10.3.1 Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2018-2029)

10.3.2 Turkey Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

10.3.4 UAE Small Interfering RNA (siRNA)-based Therapeutics Market Size and Forecast (2018-2029)

## **11 MARKET DYNAMICS**

11.1 Small Interfering RNA (siRNA)-based Therapeutics Market Drivers

11.2 Small Interfering RNA (siRNA)-based Therapeutics Market Restraints

11.3 Small Interfering RNA (siRNA)-based Therapeutics Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Small Interfering RNA (siRNA)-based Therapeutics Industry Chain

12.2 Small Interfering RNA (siRNA)-based Therapeutics Upstream Analysis

12.3 Small Interfering RNA (siRNA)-based Therapeutics Midstream Analysis

12.4 Small Interfering RNA (siRNA)-based Therapeutics Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 5. Alnylam Company Information, Head Office, and Major Competitors

Table 6. Alnylam Major Business

Table 7. Alnylam Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

Table 8. Alnylam Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. Alnylam Recent Developments and Future Plans

Table 10. Novartis Company Information, Head Office, and Major Competitors

Table 11. Novartis Major Business

Table 12. Novartis Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

Table 13. Novartis Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. Novartis Recent Developments and Future Plans

Table 15. Sylentis Company Information, Head Office, and Major Competitors

Table 16. Sylentis Major Business

Table 17. Sylentis Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

Table 18. Sylentis Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Sylentis Recent Developments and Future Plans

Table 20. Arrowhead Company Information, Head Office, and Major Competitors

Table 21. Arrowhead Major Business

Table 22. Arrowhead Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

Table 23. Arrowhead Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)



Table 24. Arrowhead Recent Developments and Future Plans

Table 25. Silence Therapeutics Company Information, Head Office, and Major Competitors

Table 26. Silence Therapeutics Major Business

Table 27. Silence Therapeutics Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

Table 28. Silence Therapeutics Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 29. Silence Therapeutics Recent Developments and Future Plans

Table 30. Dicerna Company Information, Head Office, and Major Competitors

Table 31. Dicerna Major Business

Table 32. Dicerna Small Interfering RNA (siRNA)-based Therapeutics Product and Solutions

Table 33. Dicerna Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 34. Dicerna Recent Developments and Future Plans

Table 35. Global Small Interfering RNA (siRNA)-based Therapeutics Revenue (USD Million) by Players (2018-2023)

Table 36. Global Small Interfering RNA (siRNA)-based Therapeutics Revenue Share by Players (2018-2023)

Table 37. Breakdown of Small Interfering RNA (siRNA)-based Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)

Table 38. Market Position of Players in Small Interfering RNA (siRNA)-based Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022

Table 39. Head Office of Key Small Interfering RNA (siRNA)-based Therapeutics Players

Table 40. Small Interfering RNA (siRNA)-based Therapeutics Market: Company Product Type Footprint

Table 41. Small Interfering RNA (siRNA)-based Therapeutics Market: Company Product Application Footprint

Table 42. Small Interfering RNA (siRNA)-based Therapeutics New Market Entrants and Barriers to Market Entry

Table 43. Small Interfering RNA (siRNA)-based Therapeutics Mergers, Acquisition, Agreements, and Collaborations

Table 44. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (USD Million) by Type (2018-2023)

Table 45. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Share by Type (2018-2023)

Table 46. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption

Value Forecast by Type (2024-2029)

Table 47. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2023)

Table 48. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Forecast by Application (2024-2029)

Table 49. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 50. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 51. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 52. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 53. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 54. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 55. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 56. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 57. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 58. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 59. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 60. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 61. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 62. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 63. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 64. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 65. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)



Table 66. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 67. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 68. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 69. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 70. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 71. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 72. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 73. Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 74. Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 75. Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 76. Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 77. Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 78. Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 79. Small Interfering RNA (siRNA)-based Therapeutics Raw Material

Table 80. Key Suppliers of Small Interfering RNA (siRNA)-based Therapeutics Raw Materials

## LIST OF FIGURE

s

Figure 1. Small Interfering RNA (siRNA)-based Therapeutics Picture

Figure 2. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Type in 2022

Figure 4. GIVLAARI

Figure 5. Onpattro

Figure 6. OXLUMO

Figure 7. AMVUTTRA

Figure 8. Leqvio

Figure 9. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 10. Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Application in 2022

Figure 11. AHP Picture

Figure 12. hATTR Picture

Figure 13. Other Picture

Figure 14. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 15. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 16. Global Market Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)

Figure 17. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 18. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Region in 2022

Figure 19. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 20. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 21. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 22. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 23. Middle East and Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 24. Global Small Interfering RNA (siRNA)-based Therapeutics Revenue Share by Players in 2022

Figure 25. Small Interfering RNA (siRNA)-based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 26. Global Top 3 Players Small Interfering RNA (siRNA)-based Therapeutics Market Share in 2022

Figure 27. Global Top 6 Players Small Interfering RNA (siRNA)-based Therapeutics Market Share in 2022

Figure 28. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption

Value Share by Type (2018-2023)

Figure 29. Global Small Interfering RNA (siRNA)-based Therapeutics Market Share Forecast by Type (2024-2029)

Figure 30. Global Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Share by Application (2018-2023)

Figure 31. Global Small Interfering RNA (siRNA)-based Therapeutics Market Share Forecast by Application (2024-2029)

Figure 32. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 33. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 34. North America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 35. United States Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 36. Canada Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 37. Mexico Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 38. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 39. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 40. Europe Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 41. Germany Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 42. France Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 43. United Kingdom Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 44. Russia Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 45. Italy Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 46. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 47. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 48. Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 49. China Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 50. Japan Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 51. South Korea Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 52. India Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 53. Southeast Asia Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 54. Australia Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 55. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 56. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 57. South America Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 58. Brazil Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 59. Argentina Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 60. Middle East and Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 61. Middle East and Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 62. Middle East and Africa Small Interfering RNA (siRNA)-based Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 63. Turkey Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 64. Saudi Arabia Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 65. UAE Small Interfering RNA (siRNA)-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 66. Small Interfering RNA (siRNA)-based Therapeutics Market Drivers

Figure 67. Small Interfering RNA (siRNA)-based Therapeutics Market Restraints

Figure 68. Small Interfering RNA (siRNA)-based Therapeutics Market Trends

Figure 69. Porters Five Forces Analysis

Figure 70. Manufacturing Cost Structure Analysis of Small Interfering RNA (siRNA)-based Therapeutics in 2022

Figure 71. Manufacturing Process Analysis of Small Interfering RNA (siRNA)-based Therapeutics

Figure 72. Small Interfering RNA (siRNA)-based Therapeutics Industrial Chain

Figure 73. Methodology

Figure 74. Research Process and Data Source

## I would like to order

Product name: Global Small Interfering RNA (siRNA)-based Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G4542D5CB0FCEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4542D5CB0FCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

